PLX Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
33.8M
+270.0%
9.1M
-48.9%
17.9M
+14.0%
15.7M
+54.8%
10.1M
Cost of Revenue
4.1M
-10.7%
4.6M
-44.5%
8.3M
+41.8%
5.9M
-28.2%
8.2M
Gross Profit
29.6M
+557.9%
4.5M
-52.7%
9.5M
-2.7%
9.8M
+406.4%
1.9M
Operating Expenses
8.5M
-7.5%
9.2M
+23.9%
7.4M
-14.2%
8.6M
+41.8%
6.1M
R&D
5.4M
-3.7%
5.6M
+26.1%
4.5M
-25.5%
6.0M
+72.4%
3.5M
SG&A
3.1M
-13.5%
3.5M
+20.4%
2.9M
+11.6%
2.6M
+0.8%
2.6M
Operating Income
21.1M
+554.0%
-4658000
-318.6%
2.1M
+81.8%
1.2M
+128.3%
-4145000
EBITDA
21.6M
+604.6%
-4271000
-270.6%
2.5M
+63.4%
1.5M
+140.3%
-3799000
Net Income
18.3M
+432.8%
-5504000
-333.7%
2.4M
+1336.0%
164.0K
+104.5%
-3619000
EPS (Basic)
$0.23
+428.6%
$-0.07
-333.3%
$0.03
$-0.05
EPS (Diluted)
$0.22
+414.3%
$-0.07
-333.3%
$0.03
$-0.05
Shares (Diluted)
83.0M
+10.0%
75.5M
-6.6%
80.8M
-0.6%
81.3M
+6.1%
76.6M
Protalix BioTherapeutics (PLX) — Financials